{"id":"NCT00784277","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease","officialTitle":"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Arm, Multicenter Study in Subjects With End-Stage Joint Disease to Compare the Frequency of Constipation Symptoms in SubjectsTreated With Tapentadol IR and Oxycodone IR Using a Bowel Function Patient Diary","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2008-11-03","resultsPosted":"2012-02-13","lastUpdate":"2012-02-13"},"enrollment":597,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Joint Diseases","Arthritis","Osteoarthritis"],"interventions":[{"type":"DRUG","name":"oxycodone CR","otherNames":[]},{"type":"DRUG","name":"oxycodone IR","otherNames":[]},{"type":"DRUG","name":"Tapentadol ER (CG5503)","otherNames":[]},{"type":"DRUG","name":"Tapentadol IR (CG5503)","otherNames":[]},{"type":"DRUG","name":"Tapentadol IR (CG5503)","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"},{"label":"002","type":"EXPERIMENTAL"},{"label":"003","type":"ACTIVE_COMPARATOR"},{"label":"004","type":"PLACEBO_COMPARATOR"},{"label":"005","type":"EXPERIMENTAL"},{"label":"006","type":"ACTIVE_COMPARATOR"},{"label":"007","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare bowel function/constipation that occurs during tapentadol treatment with that occuring during oxycodone treatment, as measured by the frequency of spontaneous bowel movements per week. The frequency of spontaneous bowel movements will be determined from a Bowel Function Patient Diary completed by the enrolled sujbects.","primaryOutcome":{"measure":"5-Day Sum of Pain Intensity Difference (SPID5)","timeFrame":"Day 1 to Day 5","effectByArm":[{"arm":"Placebo","deltaMin":98.6,"sd":134.73},{"arm":"Tapentadol 50 mg","deltaMin":153.1,"sd":184.07},{"arm":"Tapentadol 75 mg","deltaMin":161.8,"sd":187.31},{"arm":"Oxycodone","deltaMin":218.4,"sd":208.64}],"pValues":[{"comp":"OG000 vs OG001","p":"0.007"},{"comp":"OG000 vs OG002","p":"0.004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21494892"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":148},"commonTop":["Constipation","Nausea","Dizziness","Vomiting","Somnolence"]}}